Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
This was a single arm phase Ib study to evaluate the safety and efficacy of combined
Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing
EGFR for whom no standard treatment is available. Patients who had relapsed following their
most recent line of chemotherapy and who met all other entry criteria at Screening were
enrolled to receive Tomuzotuximab and Gatipotuzumab in combination.
During the extension phase, instead of Tomuzotuximab a commercially avalaible anti-EGFR
antibody, i.e. Cetuximab (including any approved biosimilar), Panitumumab, or Necitumumab
could be given to patients with cancers for which their use is approved.